BioXcel Therapeutics, Inc.

BTAI

US09075P1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
2.13 ^USD	-2.52%		-9.36%	-27.80%

May. 09	BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Bioxcel Therapeutics, Inc. Announces Executive Changes

October 13, 2021 at 05:03 pm EDT

On October 8, 2021, William P. Kane, Jr., Executive Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. tendered his resignation notice to the Company, effective immediately.

Latest news about BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	Apr. 22	MT
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	Apr. 22	CI
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	Apr. 10	CI
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	Mar. 25	MT
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	Mar. 15	MT
Canaccord Genuity Cuts Price Target on BioXcel Therapeutics to $7 From $20, Maintains Buy Rating	Mar. 14	MT
UBS Adjusts BioXcel Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating	Mar. 13	MT
Transcript : BioXcel Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 12	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
North American Morning Briefing : Nvidia Ignites -2-	Feb. 22	DJ
UBS Downgrades BioXcel Therapeutics to Neutral From Buy, Cuts Price Target to $4 From $9	Feb. 21	MT
BioXcel Therapeutics Shares Soar After Terminating Proposed $60 Million Stock Offering	Feb. 13	MT
BioXcel Therapeutics' BXCL701 Granted FDA Fast-Track Designation to Treat Small Cell Neuroendocrine Prostrate Cancer	Feb. 12	MT
BioXcel Therapeutics, Inc. Enter into the Third Amendment to Credit Agreement and Guaranty	Feb. 12	CI
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation	Feb. 12	DJ
BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer	Feb. 12	CI
Top Midday Decliners	Feb. 09	MT
BioXcel Therapeutics Starts $60 Million Public Offering; Shares Drop	Feb. 09	MT
Wall Street Set to Open Modestly Higher as S&P Hovers Just Above 5,000	Feb. 09	MT
Positive Quarterly Earnings Boost Exchange-Traded Funds, Equity Futures Pre-Bell Friday	Feb. 09	MT
US Futures Nudge Higher as S&P Remains Just Above 5,000	Feb. 09	MT
Top Premarket Decliners	Feb. 09	MT

Chart BioXcel Therapeutics, Inc.

Duration

Period

More charts

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Companyâs most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Annual Meeting - Poster No: 112

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for BioXcel Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.185 USD

Average target price

7.25 USD

Spread / Average Target

+231.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOXCEL THERAPEUTICS, INC.	-27.80%	82M
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	105B
BIONTECH SE	-12.56%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.86%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+5.10%	13.7B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.45B

Bio Therapeutic Drugs